Lagociclovir valactate

Lagociclovir valactate is a prodrug of Lagociclovir (HY-14844). Lagociclovir valactate is an orally active anti-HBV agent[1].

Research Areas >> Infection

Signaling Pathways >> Anti-infection >> HBV

HBV[1]

Lagociclovir valactate (20 or 60 mg/kg; p.o.; daily for 10 weeks) 在土拨鼠中显示抗土拨鼠肝炎病毒 (WHV) 活性[1]。 Animal Model: Woodchucks with chronic WHV infection[1] Dosage: 20 or 60 mg/kg Administration: Oral, daily for 10 weeks Result: Reduced WHV viremia effectively and maintained WHV DNA at a very low level. Animal Model: Woodchucks[1] Dosage: 10 or 40 mg/kg Administration: Oral (Pharmacokinetic Analysis) Result: Average pharmacokinetic parameters for Lagociclovir after oral administration of Lagociclovir valactate to healthy and chronically WHV infected woodchucks[1] Pharmacokineticparameter for Lagociclovir Healthy woodchucks (n = 4) receiving Lagociclovir valactate at 10 mg/kg Healthy woodchucks (n = 4) receiving Lagociclovir valactate at 40 mg/kg WHV-infected woodchucks (n = 14) receiving Lagociclovir valactate at 60 mg/kg Cmax (μM) 0.54 ± 0.14 2.10 ± 1.5 3.50 ± 1.9 Tmax (h) 4.10 ± 1.0 3.30 ± 1.5 2.90 ± 1.1 AUC0-∞ (μM • h/liter) 5.15 ± 1.0 10.50 ± 4.2 20.1 ± 11.3 t1/2 (h) 5.44 ± 1.2 4.20 ± 1.6 4.7 ± 0.8

[1]. Michalak TI, et al. Profound antiviral effect of oral administration of MIV-210 on chronic hepadnaviral infection in a woodchuck model of hepatitis B. Antimicrob Agents Chemother. 2009 Sep;53(9):3803-14.